Publications by authors named "G F Amoruso"
: Environmental pollution in regions like the Sarno River Basin in southern Italy significantly affects physical and psychological health. This study aimed to validate three novel psychometric tools-REST, HEAL-BDLC, and PEACE-for assessing fatigue, mood disturbances, and sleep quality in environmentally exposed populations. While correlations with heavy metal exposure will be addressed in a separate manuscript, this study focuses solely on psychometric validation.
View Article and Find Full Text PDFEffective response to upadacitinib in patients affected by prurigo nodularis and by atopic dermatitis with a predominant prurigo nodularis pattern: A multicenter case series study.
J Am Acad Dermatol
November 2024
Drug Survival of Upadacitinib and Predicting Factors of Discontinuation in Adult Patients Affected by Moderate-to-Severe Atopic Dermatitis: An Italian Multicenter Analysis.
J Clin Med
January 2024
Limited real-world data are available on upadacitinib drug survival in patients with atopic dermatitis (AD). To investigate upadacitinib drug survival, and the reasons and predictors of drug discontinuation in AD patients. All consecutive patients aged 18-75 years, affected by moderate-to-severe AD, and treated with upadacitinib for more than 1 month at dermatological clinics were included during November 2020-August 2023.
View Article and Find Full Text PDFArticle Synopsis
- Acne scars caused by acne vulgaris can significantly affect a person's physical, emotional, and social life, leading to the study of a dual-wavelength laser system for treatment.
- The study involved four healthy adults receiving 2-4 treatment sessions using lasers at 10,600 nm and 1540 nm to assess efficacy and side effects like erythema and edema.
- Results showed a mild edema index and varying degrees of erythema, with patient assessments indicating noticeable skin texture improvements and overall positive outcomes from the treatment.
Background: The management of paediatric atopic dermatitis (AD) is challenging, mostly relying on emollients and topical corticosteroids. Dupilumab, a fully human monoclonal antibody, has been recently approved for the treatment of children aged 6-11 years with moderate-to-severe AD not adequately controlled with topical therapies or when those therapies are not advisable.
Objectives: The aim of this study was to evaluate in real life the effectiveness and safety of dupilumab in the treatment of children aged from 6 to 11 years.